Continued Treatment with SGX301 in Patients with CTCL Increases Response Rates

SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma in the pivotal phase III FLASH study, which demonstrated that continued treatment twice weekly for 12 weeks increased the positive response rate.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news